275 related articles for article (PubMed ID: 26400023)
1. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).
Becker H; Suciu S; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Muus P; Pflüger KH; Hagemeijer A; Schaefer HE; Fiaccadori V; Baron F; Ganser A; Aul C; de Witte T; Wijermans PW; Lübbert M
Ann Hematol; 2015 Dec; 94(12):2003-13. PubMed ID: 26400023
[TBL] [Abstract][Full Text] [Related]
2. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
3. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.
Lübbert M; Suciu S; Hagemeijer A; Rüter B; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Muus P; Pflüger KH; Schaefer HE; Bogatyreva L; Aul C; de Witte T; Ganser A; Becker H; Huls G; van der Helm L; Vellenga E; Baron F; Marie JP; Wijermans PW;
Ann Hematol; 2016 Jan; 95(2):191-9. PubMed ID: 26596971
[TBL] [Abstract][Full Text] [Related]
4. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
5. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
Schroeder T; Rachlis E; Bug G; Stelljes M; Klein S; Steckel NK; Wolf D; Ringhoffer M; Czibere A; Nachtkamp K; Dienst A; Kondakci M; Stadler M; Platzbecker U; Uharek L; Luft T; Fenk R; Germing U; Bornhäuser M; Kröger N; Beelen DW; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2015 Apr; 21(4):653-60. PubMed ID: 25540937
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
Salim O; Toptas T; Avsar E; Yucel OK; Ozturk E; Ferhanoglu B; Geduk A; Mehtap O; Tombak A; Tiftik EN; Deveci B; Kurtoglu E; Kara O; Atagunduz IK; Tuglular TF; Undar L
Leuk Res; 2016 Jun; 45():82-9. PubMed ID: 27107658
[TBL] [Abstract][Full Text] [Related]
8. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R; Shen L; Nimer SD; Leavitt R; Raza A; Saba H
Cancer; 2006 Apr; 106(8):1794-803. PubMed ID: 16532500
[TBL] [Abstract][Full Text] [Related]
9. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Xie M; Jiang Q; Xie Y
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
[TBL] [Abstract][Full Text] [Related]
10. Azacitidine for the treatment of relapsed and refractory AML in older patients.
Itzykson R; Thépot S; Berthon C; Delaunay J; Bouscary D; Cluzeau T; Turlure P; Prébet T; Dartigeas C; Marolleau JP; Recher C; Plantier I; Stamatoullas A; Devidas A; Taksin AL; Guièze R; Caillot D; Vey N; Adès L; Ifrah N; Dombret H; Fenaux P; Gardin C
Leuk Res; 2015 Feb; 39(2):124-30. PubMed ID: 25524177
[TBL] [Abstract][Full Text] [Related]
11. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
Wanquet A; Prebet T; Berthon C; Sebert M; Roux C; Kulasekararaj A; Micol JB; Esterni B; Itzykson R; Thepot S; Recher C; Delaunay J; Dreyfus F; Mufti G; Fenaux P; Vey N
Am J Hematol; 2015 Oct; 90(10):859-63. PubMed ID: 26113240
[TBL] [Abstract][Full Text] [Related]
13. Re-evaluation of refractory anemia with excess blasts in transformation.
Ohyashiki K; Nishimaki J; Shoji N; Miyazawa K; Kimura Y; Ohyashiki JH
Leuk Res; 2001 Nov; 25(11):933-9. PubMed ID: 11597728
[TBL] [Abstract][Full Text] [Related]
14. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
[TBL] [Abstract][Full Text] [Related]
15. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
[TBL] [Abstract][Full Text] [Related]
17. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
J Clin Oncol; 2010 Feb; 28(4):562-9. PubMed ID: 20026804
[TBL] [Abstract][Full Text] [Related]
18. Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
Ye L; Ren Y; Zhou X; Mei C; Ma L; Ye X; Wei J; Xu W; Meng H; Qian W; Mai W; Lou Y; Xu G; Qian J; Lou Y; Luo Y; Xie L; Lin P; Hu C; Jin J; Tong H
J Cancer Res Clin Oncol; 2017 May; 143(5):873-882. PubMed ID: 28108816
[TBL] [Abstract][Full Text] [Related]
19. Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
Mayer J; Arthur C; Delaunay J; Mazur G; Thomas XG; Wierzbowska A; Ravandi F; Berrak E; Jones M; Li Y; Kantarjian HM
BMC Cancer; 2014 Feb; 14():69. PubMed ID: 24498872
[TBL] [Abstract][Full Text] [Related]
20. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome.
Solomon SR; Savani BN; Childs R; Montero A; Boss C; Read EJ; Leitman SF; Barrett AJ
Biol Blood Marrow Transplant; 2005 Aug; 11(8):619-26. PubMed ID: 16041312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]